Katja Seipel

University Hospital of Bern

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (19)

Collaborators (6)

Michael Daskalakis

Assistant Professor, Head of Cellular Therapy Division, Director of autologous Stem Cell Program Inselspital

Inselspital Universitätsspital Bern

Henning Nilius

University of Bern

Bruktawit Maru

Teaching Assistant

McGill University

Naomi A. Porret

Lab Head molecular diagnostics

Inselspital Universitätsspital Bern

Maureen McKeague

Assistant Professor

McGill University

Thomas Pabst

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Katja Seipel

Research Interests

Explore related searches

Contact this professor

Articles (19)

Collaborators (6)

Michael Daskalakis

Henning Nilius

Bruktawit Maru

Naomi A. Porret

Maureen McKeague

Thomas Pabst

Make your next move.

Katja Seipel

Research Interests

Explore related searches

Contact this professor

Articles (19)

Clonal Hematopoiesis and Outcomes After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with AML, Myeloma, and Lymphoma

Serum Immunoglobulin Changes in Multiple Myeloma Patients Treated with CAR T-Cell Therapy

Clinical Impact of CTLA-4 Single-Nucleotide Polymorphism in DLBCL Patients Treated with CAR-T Cell Therapy

Prognostic Value of Post-Transplant MRD Negativity in Standard Versus High- and Ultra-High-Risk Multiple Myeloma Patients

Gemtuzumab Ozogamicin and Stem Cell Mobilization for Autologous Stem Cell Transplantation in Favorable Risk Acute Myeloid Leukemia

Rising Prevalence of Low-Frequency <i>PPM1D</i> Gene Mutations after Second HDCT in Multiple Myeloma

FLT3 and IRAK4 Inhibitor Emavusertib in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia

Low-Frequency PPM1D Gene Mutations Associated with Inferior Treatment Response to CD19 Targeted CAR-T Cell Therapy in Mantle Cell Lymphoma

PARP-1 improves leukemia outcomes by inducing parthanatos during chemotherapy

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia

Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma

Low-Frequency PPM1D Gene Mutations Affect Treatment Response to CD19-Targeted CAR T-Cell Therapy in Large B-Cell Lymphoma

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia

Collaborators (6)

Michael Daskalakis

Henning Nilius

Bruktawit Maru

Naomi A. Porret

Maureen McKeague

Thomas Pabst

Make your next move.